Exicure receives NASDAQ notice for failing equity requirement Jun 10, 2026 04:01PM
Exicure receives Nasdaq delinquency notice, files delayed quarterly report Jun 1, 2026 04:01PM
Exicure appoints Yoontae Han to board and audit committee Apr 10, 2026 04:19PM
Exicure settles stockholder derivative lawsuit for $675,000 Apr 2, 2026 04:01PM
Exicure publishes burixafor stem cell mobilization study results Feb 5, 2026 07:02AM


Oct 6, 2025 07:01AM Exicure nears phase 2 data readout for blood cancer drug burixafor
Aug 11, 2025 06:40AM Exicure Inc. (XCUR) Misses Q2 EPS by 41c
May 28, 2025 04:58PM Exicure Inc. (XCUR) Received Nasdaq Delinquency Notice
Mar 13, 2025 04:10PM Exicure Inc. (XCUR) Issues New Patent in Australia
Jan 27, 2025 10:01AM Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
Jan 22, 2025 04:02PM Exicure Inc. (XCUR) Announces Purchase Agreement with GPCR Therapeutics Inc.
Sep 18, 2024 04:01PM Exicure Inc. (XCUR) Receives Extension from Nasdaq Hearings Panel
Aug 26, 2024 09:08AM Exicure Inc. (XCUR) Announces 1-for-5 Reverse Stock Split
Aug 19, 2024 10:31AM Exicure Inc. (XCUR) Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
Aug 1, 2024 04:01PM Exicure (XCUR) Receives Positive Listing Determination from Nasdaq